{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:27:34Z","timestamp":1790440054803,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ijcard.2015.05.125","type":"journal-article","created":{"date-parts":[[2015,5,22]],"date-time":"2015-05-22T16:14:51Z","timestamp":1432311291000},"page":"20-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["The renal effects of mineralocorticoid receptor antagonists"],"prefix":"10.1016","volume":"200","author":[{"given":"Stefano","family":"Bianchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Batini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bigazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2015.05.125_bb0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF02155834","article-title":"Isolation from the adrenals of a new crystalline hormone with especially high effectiveness on mineral metabolism","volume":"9","author":"Simpson","year":"1953","journal-title":"Experientia"},{"key":"10.1016\/j.ijcard.2015.05.125_bb0010","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1254\/jphs.08R02CR","article-title":"Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury","volume":"108","author":"Kiyomoto","year":"2008","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2015.05.125_bb0020","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1681\/ASN.2004090804","article-title":"Remission of existing glomerulosclerosis by inhibition of aldosterone","volume":"16","author":"Aldigier","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.107.109645","article-title":"Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats","volume":"52","author":"Michea","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2015.05.125_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/joe.1.06017","article-title":"The new biology of aldosterone","volume":"186","author":"Connell","year":"2005","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0035","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.mce.2011.06.026","article-title":"Non-adrenal synthesis of aldosterone: a reality check","volume":"350","author":"MacKenzie","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0040","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1097\/01.ASN.0000083982.74108.54","article-title":"Non-genomic vascular action of aldosterone in the glomerular microcirculation","volume":"14","author":"Arima","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0045","first-page":"73","article-title":"2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"KDIGO","year":"2013","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0050","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0055","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ki.1982.14","article-title":"Plasma aldosterone concentration in chronic renal failure","volume":"21","author":"Hene","year":"1982","journal-title":"Kidney Int."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0060","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0065","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/ki.1992.45","article-title":"Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level","volume":"41","author":"Quan","year":"1992","journal-title":"Kidney Int."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0070","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.105.539122","article-title":"Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria","volume":"112","author":"Quinkler","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.05.125_bb0075","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1097\/HJH.0b013e328354f65b","article-title":"Plasma renin activity and the aldosterone-to-renin ratio are associated with the development of chronic kidney disease: the Ohasama Study","volume":"30","author":"Terata","year":"2012","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0080","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1681\/ASN.2010010085","article-title":"A multi-marker approach to predict incident CKD and microalbuminuria","volume":"21","author":"Fox","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0085","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","article-title":"Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats","volume":"33","author":"Rocha","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2015.05.125_bb0090","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1152\/ajprenal.00197.2009","article-title":"Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats","volume":"297","author":"Du","year":"2009","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0095","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/j.1523-1755.2004.00913.x","article-title":"Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats","volume":"66","author":"Fujisawa","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/01.HYP.6.2_Pt_2.I183","article-title":"Role of renal hemodynamics and arterial pressure in aldosterone \u201cescape\u201d","volume":"6","author":"Hall","year":"1984","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2015.05.125_bb0105","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0002-9610(64)90252-1","article-title":"Clinical characteristics of primary aldosteronism from an analysis of 145 cases","volume":"107","author":"Conn","year":"1964","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0110","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","article-title":"Renal damage in primary aldosteronism: results of the PAPY study","volume":"48","author":"Rossi","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2015.05.125_bb0115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/EJE-12-0631","article-title":"Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism","volume":"168","author":"Fourkiotis","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0120","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/j.ajkd.2005.03.007","article-title":"Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study","volume":"46","author":"Bianchi","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0130","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2015.05.125_bb0135","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0140","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironalactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function","volume":"24","author":"Van den Meiracker","year":"2006","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0145","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0150","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.cardfail.2007.04.008","article-title":"Worsening renal function and prognosis in heart failure: systematic review and meta-analysis","volume":"13","author":"Damman","year":"2007","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0155","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa041365","article-title":"Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction","volume":"351","author":"Anavekar","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0160","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1681\/ASN.2006010063","article-title":"Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction","volume":"17","author":"Jose","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0165","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/CIRCULATIONAHA.111.028282","article-title":"Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival study","volume":"125","author":"Rossignol","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.05.125_bb0170","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0175","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure:insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0180","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0185","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0190","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.05.125_bb0195","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527315011882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527315011882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T07:23:24Z","timestamp":1537601004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527315011882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":39,"alternative-id":["S0167527315011882"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2015.05.125","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725539265.793507574","asserted-by":"object"}]},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The renal effects of mineralocorticoid receptor antagonists","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2015.05.125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}